Peptide Therapies for Chemotherapy Side Effects
Peptide Therapies for Chemotherapy Side Effects
60%
Anamorelin reduced cisplatin-induced acute emesis by 60% when delivered centrally in ferret models, while also preventing 24% of chemotherapy-induced weight loss.
Lu et al., Physiology & Behavior, 2024
Lu et al., Physiology & Behavior, 2024
View as imageChemotherapy kills cancer cells, but it also damages healthy tissue throughout the body. The resulting side effects, including nausea, muscle wasting, oral mucositis, peripheral neuropathy, and cardiac damage, are responsible for dose reductions, treatment delays, and significant suffering. Peptide-based therapies have emerged as targeted interventions for several of these side effects, with three classes already in clinical use: NK1 receptor antagonists that block substance P-driven nausea, ghrelin receptor agonists that combat cancer cachexia, and keratinocyte growth factor (palifermin) that protects mucosal tissue. This article surveys the full landscape of peptide therapies for chemotherapy side effects, covering what is approved, what is in clinical trials, and where the evidence remains preclinical. For focused coverage of specific topics, see our articles on ghrelin agonists for cancer cachexia and peptides for oral mucositis.
Key Takeaways
- Aprepitant (Emend), an NK1 receptor antagonist that blocks substance P signaling, is standard of care for preventing delayed chemotherapy-induced nausea alongside 5-HT3 antagonists
- Anamorelin, an oral ghrelin receptor agonist, improved lean body mass by 1.56 kg and appetite in phase III trials for cancer cachexia and was approved in Japan in December 2020
- In ferret models, anamorelin reduced cisplatin-induced acute emesis by 60% when delivered centrally and prevented approximately 24% of chemotherapy-induced weight loss (Lu et al., 2024)
- Palifermin (Kepivance), a recombinant keratinocyte growth factor, reduced severe oral mucositis from 98% to 63% in stem cell transplant patients and received FDA approval in 2004
- Natriuretic peptides (BNP, NT-proBNP) serve as biomarkers for detecting chemotherapy-induced cardiotoxicity from anthracyclines like doxorubicin
- Substance P/NK1 receptor signaling has dual relevance: mediating chemotherapy nausea and potentially promoting tumor growth in certain cancers
Substance P and Chemotherapy-Induced Nausea
Chemotherapy-induced nausea and vomiting (CINV) occurs in two phases. The acute phase (first 24 hours) is primarily driven by serotonin (5-HT3) release from damaged intestinal enterochromaffin cells. The delayed phase (days 2-5) is mediated by substance P, an 11-amino-acid neuropeptide that activates neurokinin-1 (NK1) receptors in the brainstem's vomiting center.[1]
This discovery transformed antiemetic therapy. Before NK1 receptor antagonists, delayed CINV was poorly controlled because 5-HT3 antagonists like ondansetron had limited efficacy beyond the acute phase. The development of aprepitant (Emend), the first NK1 receptor antagonist approved for CINV prevention, addressed this gap by blocking substance P at its receptor in the central nervous system.
Aprepitant crosses the blood-brain barrier with high selectivity, occupying greater than 90% of NK1 receptors in the brain at therapeutic doses as demonstrated by PET imaging studies. In clinical trials, adding aprepitant to standard 5-HT3 antagonist plus dexamethasone regimens reduced the rate of delayed emesis from highly emetogenic chemotherapy (particularly cisplatin-based regimens) by approximately 20 percentage points compared to the two-drug combination alone.[1]
The NK1 receptor antagonist class has expanded to include fosaprepitant (an intravenous prodrug), netupitant (combined with palonosetron as NEPA), and rolapitant. All target the same peptide signaling pathway: blocking substance P from activating NK1 receptors in the area postrema and nucleus tractus solitarius. Current NCCN guidelines recommend triple therapy (NK1 antagonist + 5-HT3 antagonist + dexamethasone) for highly emetogenic chemotherapy regimens.
The Dual Role of Substance P in Cancer
Substance P's role in oncology extends beyond nausea. The NK1 receptor is overexpressed in several tumor types, and substance P/NK1 signaling promotes tumor cell proliferation, angiogenesis, and migration. Munoz et al. (2015) reviewed the evidence for NK1 receptor antagonists as potential anticancer agents, documenting that aprepitant and related compounds induced apoptosis in tumor cell lines from multiple cancer types in vitro.[2]
Garcia-Recio et al. (2015) demonstrated that substance P transmodulates HER2 and EGFR signaling in breast cancer cells through c-Src and metalloproteinase activation, providing a molecular mechanism by which the peptide could drive tumor progression.[3]
This creates a compelling therapeutic convergence: NK1 receptor antagonists already prescribed for CINV may simultaneously inhibit tumor-promoting signaling. Whether the doses used for antiemetic therapy achieve meaningful anticancer concentrations at tumor sites remains unresolved. Clinical trials specifically evaluating NK1 antagonists as anticancer agents are limited, but the dual pharmacology is an active area of investigation. For broader context on peptides that directly target tumors, see Anticancer Peptides: How They Selectively Kill Tumor Cells.
Ghrelin Agonists for Cancer Cachexia
Cancer cachexia, a syndrome of involuntary weight loss, muscle wasting, and anorexia, affects up to 80% of patients with advanced cancer and directly contributes to mortality. The condition involves dysregulated ghrelin signaling: despite elevated circulating ghrelin levels, cancer patients show blunted appetite and anabolic responses, a state sometimes described as "ghrelin resistance."[4]
Anamorelin hydrochloride is an oral ghrelin receptor agonist developed to overcome this resistance through supraphysiological receptor activation. In preclinical studies, anamorelin demonstrated potent ghrelin receptor binding affinity, significant appetite enhancement, and improvements in body weight and lean body mass without promoting tumor growth.[5]
The ROMANA phase III clinical trials tested anamorelin (100 mg daily oral) in patients with non-small cell lung cancer and cachexia. Results showed a mean lean body mass increase of 1.56 kg assessed by dual-energy X-ray absorptiometry. Appetite scores improved, and growth hormone and IGF-1 levels increased. The drug was well tolerated with no dose-limiting toxicities identified.[6]
Anamorelin received regulatory approval in Japan on December 11, 2020, for cancer cachexia in four cancer types: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. This made it the first ghrelin receptor agonist approved for any cachexia indication worldwide. However, anamorelin was not approved in Europe because improvements in lean body mass did not consistently translate to functional gains as measured by handgrip strength.[7]
The disconnect between body composition improvement and functional improvement represents a fundamental challenge in cachexia drug development. Gaining lean mass is not the same as gaining functional muscle. Whether earlier intervention (before significant wasting occurs) could produce better functional outcomes remains an open question. A 2024 observational study from Japan found that early administration of anamorelin improved outcomes in gastrointestinal cancer patients, with a mean body weight increase of 1.89 kg, supporting the hypothesis that timing matters.
A meta-analysis published in Scientific Reports (2023) synthesized data across multiple randomized trials, reporting that anamorelin significantly increased total body weight (mean difference 1.73 kg, 95% CI 1.34-2.13), lean body mass (mean difference 1.06 kg, 95% CI 0.30-1.81), and quality of life scores compared to placebo. These aggregate results reinforce the drug's efficacy for body composition endpoints while underscoring the persistent gap in functional measures.
For detailed coverage of the ghrelin-cachexia connection, see Ghrelin Agonists for Cancer Cachexia: Fighting Wasting with Appetite Peptides and for the broader biology of ghrelin, Ghrelin: The Hunger Hormone That Rises Before Meals.
Ghrelin Agonists as Antiemetics
Beyond cachexia, ghrelin receptor agonists show promise for chemotherapy-induced nausea, an application that could make them dual-purpose supportive care agents.
Rudd et al. (2018) tested HM01, a brain-penetrating ghrelin agonist, both alone and combined with the 5-HT3 antagonist palonosetron and the NK1 antagonist netupitant against cisplatin-induced emesis in the Suncus murinus (house musk shrew) model. HM01 demonstrated antiemetic effects and enhanced the efficacy of standard antiemetic combinations.[8]
Lu et al. (2024) extended this work to ferrets, the gold-standard animal model for emesis research. Both anamorelin (1-3 mg/kg) and ipamorelin (1-3 mg/kg) administered intraperitoneally prevented approximately 24% of cisplatin-induced weight loss during the delayed phase. Neither compound reduced emesis via peripheral injection. When anamorelin was delivered intracerebroventricularly (directly into the brain), it reduced acute emesis by 60% and improved food and water consumption by 20-40% during the acute phase.[9]
This finding has clear translational implications: brain penetration is required for the antiemetic effect. Current oral anamorelin formulations may not achieve sufficient brain concentrations for antiemetic activity, which could explain why this effect has not been prominently observed in human cachexia trials. Developing brain-penetrant ghrelin agonist formulations could unlock a comprehensive supportive care drug that addresses both cachexia and nausea through a single mechanism.
Howick et al. (2020) further characterized anamorelin's behavioral effects, demonstrating appetite-stimulating and reward-related effects in rodent models that support its dual role in addressing the anorexia and malaise components of chemotherapy.[10]
Palifermin for Oral Mucositis
Oral mucositis, the painful inflammation and ulceration of the mouth and throat lining, occurs in up to 98% of patients receiving high-dose chemotherapy with stem cell transplant. It causes severe pain requiring opioid analgesia, impairs nutrition, increases infection risk, and can necessitate treatment delays.
Palifermin (Kepivance) is a recombinant human keratinocyte growth factor (KGF) that binds KGF receptors on epithelial cell surfaces throughout the mouth, esophagus, and gastrointestinal tract. The 140-amino-acid protein promotes epithelial cell proliferation, differentiation, and migration while also upregulating detoxifying enzymes and suppressing proinflammatory cytokines.
In the pivotal phase III trial, palifermin reduced the incidence of WHO grade 3-4 (severe) oral mucositis from 98% in the placebo group to 63% in the treatment group among patients undergoing stem cell transplant for hematological malignancies. Treated patients also experienced shorter duration of mucositis, decreased pain, reduced opioid use, lower rates of febrile neutropenia, and decreased need for total parenteral nutrition.
Palifermin received FDA approval on December 15, 2004, making it the first drug specifically approved for preventing oral mucositis. Its indication is limited to hematological malignancies receiving myeloablative therapy; it is not approved for solid tumor patients because KGF receptors are present on some tumor types, raising theoretical concerns about stimulating cancer growth.
The dosing protocol requires three consecutive daily intravenous doses of 60 mcg/kg before and after myelotoxic therapy, with the last pre-conditioning dose given 24-48 hours before chemotherapy begins. This narrow therapeutic window and the requirement for six total doses over the transplant period limits palifermin's utility in non-transplant settings where mucositis is also prevalent but less predictable in timing.
Other growth factor peptides have been investigated for mucositis but have not reached the same level of clinical validation. Transforming growth factor beta-3, recombinant human interleukin-11, and various epithelial growth factors have shown protective effects in preclinical and early clinical studies, but none have matched palifermin's phase III efficacy data. The mucositis treatment space remains an area of active peptide development.
For detailed coverage of palifermin and other peptide approaches to oral mucositis, see Peptides for Oral Mucositis: Healing the Mouth After Chemo.
Natriuretic Peptides as Cardiotoxicity Biomarkers
Anthracycline chemotherapy agents (doxorubicin, epirubicin, daunorubicin) cause dose-dependent cardiac damage that can progress to heart failure. Early detection of cardiotoxicity allows dose modification before irreversible damage occurs.
Brain natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) have emerged as the leading peptide biomarkers for this purpose. These 32-amino-acid peptides are released by cardiac myocytes under hemodynamic stress. Elevated BNP or NT-proBNP levels during anthracycline treatment can signal subclinical cardiac dysfunction before it becomes symptomatic or detectable on echocardiography.
Multiple studies have shown that persistent BNP elevation after anthracycline dosing predicts subsequent development of reduced ejection fraction and clinical heart failure. Serial BNP monitoring during chemotherapy has been incorporated into cardio-oncology surveillance protocols at many cancer centers, allowing oncologists to modify treatment intensity before cumulative cardiac damage becomes irreversible.
Natriuretic peptide monitoring represents a different model of peptide utility in oncology: the peptide itself is not the therapy but rather the diagnostic tool that guides treatment decisions. For broader context on natriuretic peptide biology, see ANP: The Atrial Peptide That Lowers Blood Pressure.
Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) affects 30-70% of patients receiving neurotoxic agents (taxanes, platinum compounds, vinca alkaloids). Symptoms include numbness, tingling, and pain in the hands and feet that can persist for months or years after treatment completion. Current treatment options are extremely limited: duloxetine is the only pharmacological agent with evidence supporting its use for established CIPN.
Peptide-based approaches to CIPN remain largely preclinical. Spider venom-derived peptides that selectively block TRPA1 channels have shown antinociceptive effects in bortezomib-induced neuropathy models. Neuroprotective peptides including BDNF, NGF, and erythropoietin have been investigated for their ability to protect sensory neurons from chemotherapy damage, but none have reached approval for this indication.
The challenge is that neuroprotective growth factors carry the risk of supporting tumor survival. Any peptide therapy for CIPN must demonstrate selectivity for sensory neurons over tumor cells, a pharmacological hurdle that has slowed development in this space. Calcitonin gene-related peptide (CGRP) and substance P, both expressed in sensory neurons, are involved in CIPN pathophysiology and represent potential therapeutic targets, though their roles are complex and bidirectional.
Erythropoiesis-Stimulating Agents
Chemotherapy-induced anemia affects the majority of patients receiving cytotoxic regimens. Erythropoietin (EPO) and its longer-acting analog darbepoetin alfa are glycoprotein hormones (165 amino acids) that stimulate red blood cell production by binding EPO receptors on erythroid progenitor cells in bone marrow.
These agents reduce the need for blood transfusions and improve quality of life in chemotherapy patients with hemoglobin below 10 g/dL. However, their use became controversial after clinical trials revealed that targeting hemoglobin levels above 12 g/dL increased the risk of thromboembolic events and potentially accelerated tumor progression in certain cancer types. Current guidelines recommend using the lowest dose necessary to avoid transfusion, with careful hemoglobin monitoring.
The EPO story illustrates a recurring theme in peptide oncology: biological signals that support normal tissue recovery can also support tumor biology. This tension between therapeutic benefit and oncologic risk defines the development landscape for many peptide-based supportive care agents. The same principle applies to growth factors, ghrelin agonists, and any peptide that promotes cell survival or proliferation in the context of active malignancy.
Peptide Hormones Disrupted by Chemotherapy
Chemotherapy disrupts multiple peptide hormone systems beyond the ones directly targeted by current therapies. Gonadotropin-releasing hormone (GnRH) axis suppression from alkylating agents causes premature ovarian failure and testosterone deficiency, contributing to fatigue, bone loss, and reduced quality of life. In breast cancer specifically, GnRH agonists are intentionally used to suppress ovarian function as part of hormonal therapy, an example of weaponizing a peptide axis against cancer. For more on this application, see GnRH Agonists for Breast Cancer: Hormonal Suppression Therapy.
Chemotherapy also alters gastrointestinal peptide profiles. A 2025 study in the Journal of Pharmaceutical Health Care and Sciences measured plasma levels of five gastrointestinal peptides (substance P, neuropeptide Y, motilin, ghrelin, and leptin) in patients receiving chemotherapy and found significant associations between peptide imbalances and both CINV severity and anorexia. These findings suggest that the disruption of multiple peptide signaling systems, not just substance P or ghrelin alone, contributes to the constellation of chemotherapy side effects.
Neuropeptide Y (NPY), in particular, functions as a stress-response peptide that modulates appetite, anxiety, and immune function. Chemotherapy-induced changes in NPY levels may contribute to the fatigue, anxiety, and appetite loss that patients experience but that current supportive care inadequately addresses. Understanding these broader peptide disruptions may eventually enable more comprehensive supportive care strategies that address the systemic peptide imbalance caused by cytotoxic therapy rather than targeting individual symptoms in isolation.
The Emerging Pipeline
Several peptide-based approaches are in earlier stages of development for chemotherapy side effects:
Melanocortin-4 receptor (MC4R) antagonists target the central melanocortin system, which mediates cancer-induced anorexia independently of the ghrelin pathway. TCMCB07, a synthetic peptide MC4R antagonist with blood-brain barrier transport properties, has shown promise in stimulating food intake and preserving muscle mass in preclinical cachexia models.
GLP-1 receptor agonists, already approved for diabetes and obesity, are being studied for potential interactions with chemotherapy. Rather than treating side effects, the concern is that GLP-1 agonists may worsen chemotherapy-induced nausea and delay gastric emptying, complicating oral drug absorption. Oncologists are increasingly encountering patients on semaglutide or tirzepatide who need chemotherapy, creating a practical clinical question about drug interactions.
Thymosin alpha 1 has been studied as an immune reconstitution agent following chemotherapy-induced immunosuppression, particularly in hepatocellular carcinoma and non-small cell lung cancer. The 28-amino-acid peptide enhances T-cell and natural killer cell function, potentially reducing infection risk during the post-chemotherapy nadir period.
Where the Field Stands
Peptide therapies for chemotherapy side effects span the full development spectrum, from FDA-approved drugs to preclinical candidates.
Established in clinical practice: NK1 receptor antagonists (aprepitant, fosaprepitant, netupitant, rolapitant) for CINV prevention. Palifermin for mucositis in stem cell transplant. Erythropoiesis-stimulating agents for chemotherapy-induced anemia. BNP/NT-proBNP for cardiotoxicity monitoring.
Approved but geographically limited: Anamorelin for cancer cachexia (Japan only; not approved in US or Europe).
In active investigation: Ghrelin agonists as dual-purpose antiemetic and anti-cachexia agents. NK1 antagonists as potential anticancer drugs. MC4R antagonists for cancer anorexia.
Preclinical or early stage: Peptide approaches to CIPN. Thymosin alpha 1 for post-chemotherapy immune reconstitution.
The most promising near-term advance is the development of brain-penetrant ghrelin agonist formulations that could simultaneously address cachexia and nausea, two of the most debilitating chemotherapy side effects, through a single oral medication.[9] The regulatory pathway established by anamorelin's approval in Japan, combined with the mechanistic insights from central delivery studies, positions this class for expanded clinical investigation.
The broader lesson from peptide-based supportive oncology is that the body's own signaling molecules, substance P, ghrelin, keratinocyte growth factor, natriuretic peptides, are deeply involved in both the pathology of chemotherapy side effects and their potential solutions. Targeting these peptide systems with precision, blocking substance P to stop nausea, activating ghrelin receptors to reverse wasting, supplementing KGF to protect mucosal barriers, represents a fundamentally different approach from managing symptoms after they appear.
The Bottom Line
Peptide-based therapies address multiple chemotherapy side effects through the body's own signaling systems. NK1 receptor antagonists (blocking substance P) are standard of care for delayed nausea. Anamorelin (a ghrelin agonist) is approved in Japan for cancer cachexia. Palifermin (keratinocyte growth factor) prevents severe mucositis in stem cell transplant patients. Natriuretic peptides serve as biomarkers for detecting cardiotoxicity. The next frontier is brain-penetrant ghrelin agonists that could simultaneously treat both cachexia and nausea, and NK1 antagonists that may have anticancer effects alongside their antiemetic role.